Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
CD19-specific CAR-T Cells in CLL/SLL and DLBCL

(CAR) and manufactured with a new process. CAR-T cells will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in

  • 98 views
  • 10 Mar, 2022
  • 19 locations
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as …

  • 0 views
  • 27 May, 2022
  • 1 location
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

assess the efficacy and the safety of R-CHOP in combination with ibrutinib for 6 cycles followed by ibrutinib maintenance for 18 months in ABC-DLBCL patients achieving at least a PR after the induction

ibrutinib
platelet count
growth factor
cancer
measurable disease
  • 0 views
  • 10 Apr, 2022
  • 33 locations
RICE-ibrutinib in Relapsed DLBCL

This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.

ibrutinib
diffuse large b-cell lymphoma refractory
lymphoma
anthracyclines
gilbert's syndrome
  • 184 views
  • 27 Jan, 2022
  • 1 location
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

activity in WM and its low toxicity, Ibrutinib was approved for the treatment of WM by the European Medicines Agency (EMA). However, also Ibrutinib fails to induce CRs and the VGPR rate is 16% in relapsed

ibrutinib
platelet count
bone marrow procedure
dexamethasone
lymphoma
  • 0 views
  • 09 Apr, 2022
  • 14 locations
Ibrutinib and Rituxan for Chronic GVHD

This is a phase II trial evaluating the safety and efficacy of the combination of Ibrutinib and Rituximab as primary treatment of chronic GVHD. We plan to enroll 35 patients on this study

rituximab
ibrutinib
immunosuppressive agents
chronic graft versus host disease
immunosuppression
  • 12 views
  • 26 Apr, 2022
  • 1 location
Pembrolizumab, Ibrutinib and Rituximab in PCNSL

study are: Pembrolizumab (MK3475) Ibrutinib Rituximab (or biosimilar)

hormonal contraception
platelet count
ibrutinib
oophorectomy
aptt
  • 0 views
  • 28 Jul, 2022
  • 1 location
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrm's macroglobulinemia (WM). The study will evaluate this combination in two

neutrophil count
ibrutinib
measurable disease
human chorionic gonadotropin
igm level
  • 1 views
  • 17 Feb, 2022
  • 1 location
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

This is a Phase 1 clinical trial, a type of research study. The purpose of this phase 1 clinical trial is to find out whether a new study drug, ibrutinib, is safe in patients with T-cell non

platelet count
refractory t-cell non-hodgkin lymphoma
peripheral t-cell lymphoma
thrombocytopenia
hormonal therapy
  • 41 views
  • 24 Jan, 2022
  • 2 locations
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune

monoclonal protein
lymphoid leukemia
ibrutinib
monoclonal antibodies
  • 1 views
  • 11 Jul, 2022
  • 1 location